Abstract
Genome mining study showed that marine-derived Streptomyces sp. GMY01 is a potential actinobacteria with abundant of secondary metabolite and anticancer activity. The study aimed to evaluate bioassay guided fractionation for antiplasmodial screening of GMY01 extract and to predict compound on active fractions. Ethyl acetate fraction was obtained from 11 days fermentation product of GMY01 and then it was fractionated using n-hexane and methanol solvent. Refractionated was applied using flash chromatography and column chromatography. Antiplasmodial assay was performed on Plasmodium falciparum FCR3 by microscopic method using thin blood smear + Giemsa stain, and flow cytometry method using SYBR Green I stain. Toxicity assay was performed on Vero cells line. Main constituent of active fraction was analyzed using LCMS/MS. The result of the study showed that ethyl acetate-methanol fraction has high antiplasmodial activity (IC50=3.96 µg/mL) with very low toxicity on Vero cells (IC50=30,072 µg/mL). Bioassay guided fractionation resulted F4.7 as highest Plasmodium inhibition (94.3% at 5 µg/mL) and was confirmed by microscopic and flow cytometry assay. Main constituent analysis showed C10H13NO (163.09971 Da) as mayor compound and predicted as nonribosomal polyketide synthetase (NRPS) secondary metabolite.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
